Explore opportunities
Search by company name (Bolden, Pax, OncoLux, Nabsys), asset id, or title. Each card links to a full dossier with cited evidence.
Loading filters…
DARPA-scale wireless neurograins—dense cortical sensing without Utah-array tethers.
Brown OTL spinout after ~$19M DARPA + UH2—hardware path parallel to BrainGate decode IP.
Recruiting speech and tablet iBCI trials—decode IP distinct from electrode vendors.
U01 + VA funding with NCT05724173 family—consortium license or device co-development.
Open dossierDARPA intelligent spinal interface—SCI rehab IDE distinct from cortical BCI.
DARPA $6.3M + NCT04302259—medtech strategic or SPV vs wireless neurograins.
ASO switch for neural stem-cell quiescence—Brown Fallon/Webb science in a Slater-backed Providence newco.
NIA STTR + $1.5M pre-seed (Slater, Lifespan Vision)—formation capital before Big Pharma neurogenesis comparables.
Open dossierFoundational BMI decode patents—FTO diligence essential for new neurotech entrants.
Royalty or field-of-use license vs wireless/speech sub-families.
Open dossierKIWI wireless micro-implant BCI—Providence HQ with BrainGate FTO diligence.
Nurosene partnership + strategic path—harvest Howard/ni2o USPTO vs Brown patents.
Open dossier